Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Journal of the American Academy of Audiology
|
October 4, 2018
Using Microphone Technology to Improve Speech Perception in Noise in Children with Cochlear Implants
Patti M Johnstone, Kristen E T Mills, Elizabeth Humphrey, et al.
The Patient
|
June 28, 2021
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
Sarah-Jane Anderson, Miranda Murray, David Cella, et al.
The Journal of Pain
|
February 5, 2011
A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain
Gordon Irving, Janos Pénzes, Brian Ramjattan, et al.
Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
|
June 27, 2019
Outcomes Following Dynamic Compression Bracing for Pectus Carinatum
Charlene Dekonenko, Robert M Dorman, Amy Pierce, et al.
Infectious Diseases and Therapy
|
April 26, 2025
Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV
Nilay Thakkar, Rulan Griesel, Amy Pierce, et al.
Infectious Diseases and Therapy
|
April 2, 2025
Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV
Nilay Thakkar, Rulan Griesel, Amy Pierce, et al.
Frontiers in Immunology
|
June 12, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study
Josep M Llibre, Judith A Aberg, Sharon Walmsley, et al.
The New England Journal of Medicine
|
March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, Judith Aberg, Gilles Pialoux, et al.
Infectious Diseases and Therapy
|
September 26, 2023
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
Judith A Aberg, Bronagh Shepherd, Marcia Wang, et al.
Antimicrobial Agents and Chemotherapy
|
May 3, 2022
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Margaret Gartland, Pedro Cahn, Edwin DeJesus, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Journal of the American Academy of Audiology
|
October 4, 2018
Using Microphone Technology to Improve Speech Perception in Noise in Children with Cochlear Implants
Patti M Johnstone, Kristen E T Mills, Elizabeth Humphrey, et al.
The Patient
|
June 28, 2021
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
Sarah-Jane Anderson, Miranda Murray, David Cella, et al.
The Journal of Pain
|
February 5, 2011
A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain
Gordon Irving, Janos Pénzes, Brian Ramjattan, et al.
Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
|
June 27, 2019
Outcomes Following Dynamic Compression Bracing for Pectus Carinatum
Charlene Dekonenko, Robert M Dorman, Amy Pierce, et al.
Infectious Diseases and Therapy
|
April 26, 2025
Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV
Nilay Thakkar, Rulan Griesel, Amy Pierce, et al.
Infectious Diseases and Therapy
|
April 2, 2025
Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV
Nilay Thakkar, Rulan Griesel, Amy Pierce, et al.
Frontiers in Immunology
|
June 12, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study
Josep M Llibre, Judith A Aberg, Sharon Walmsley, et al.
The New England Journal of Medicine
|
March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, Judith Aberg, Gilles Pialoux, et al.
Infectious Diseases and Therapy
|
September 26, 2023
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
Judith A Aberg, Bronagh Shepherd, Marcia Wang, et al.
Antimicrobial Agents and Chemotherapy
|
May 3, 2022
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Margaret Gartland, Pedro Cahn, Edwin DeJesus, et al.
Page
of 3